Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinoma
- 30 October 2018
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 144 (1), 190-199
- https://doi.org/10.1002/ijc.31893
Abstract
Tyrosine kinase inhibitors (TKI) have improved prognosis in metastatic anaplastic lymphoma kinase (ALK)‐driven lung adenocarcinoma, but patient outcomes vary widely. We retrospectively analyzed the clinical course of all cases with assessable baseline TP53 status and/or ALK fusion variant treated at our institutions (n = 102). TP53 mutations were present in 17/87 (20%) and the echinoderm microtubule‐associated protein‐like 4 (EML4)‐ALK variant 3 (V3) in 41/92 (45%) patients. The number of metastatic sites at diagnosis was affected more by the presence of V3 than by TP53 mutations, and highest with both factors (mean 5.3, p < 0.001). Under treatment with ALK TKI, progression‐free survival (PFS) was shorter with either TP53 mutations or V3, while double positive cases appeared to have an even higher risk (hazard ratio [HR] = 2.9, p = 0.015). The negative effect of V3 on PFS of TKI‐treated patients was strong already in the first line (HR = 2.5, p = 0.037) and decreased subsequently, whereas a trend for PFS impairment under first‐line TKI by TP53 mutations became stronger and statistically significant only when considering all treatment lines together. Overall survival was impaired more by TP53 mutations (HR = 4.9, p = 0.003) than by V3 (HR = 2.4, p = 0.018), while patients with TP53 mutated V3‐driven tumors carried the highest risk of death (HR = 9.1, p = 0.02). Thus, TP53 mutations and V3 are independently associated with enhanced metastatic spread, shorter TKI responses and inferior overall survival in ALK+ lung adenocarcinoma. Both markers could assist selection of cases for more aggressive management and guide development of novel therapeutic strategies. In combination, they define a patient subset with very poor outcome.Funding Information
- Deutsche Zentrum für Lungenforschung
This publication has 36 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Links between mutant p53 and genomic instabilityJournal of Cellular Biochemistry, 2011
- A Novel, Highly Sensitive Antibody Allows for the Routine Detection ofALK-Rearranged Lung Adenocarcinomas by Standard ImmunohistochemistryClinical Cancer Research, 2010
- Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawalNature, 2010
- Clinical Outcomes and Correlates of TP53 Mutations and CancerCold Spring Harbor Perspectives in Biology, 2009
- The first 30 years of p53: growing ever more complexNature Reviews Cancer, 2009
- Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinaseNature Protocols, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- The role of p53 in treatment responses of lung cancerBiochemical and Biophysical Research Communications, 2005